DECLARE-TIMI 58

The DECLARE-TIMI 58 CVOT assessed the cardiovascular safety of dapagliflozin in patients with type 2 diabetes with high CV risk, or prior CV events. This module details the results.

DECLARE-TIMI 58
Rate this content
  • DECLARE-TIMI 58
  • DECLARE-TIMI 58
  • DECLARE-TIMI 58
  • DECLARE-TIMI 58: trial design
  • DECLARE-TIMI 58: key inclusion and exclusion criteria
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go